Home
MGX

MGX

METAGENOMI INC

as 05-20-2024 1:32pm EST

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

#6 in Best New Stocks

#47 in Best Micro Cap Stocks

Founded:	2018	Country:	United States
Employees:	N/A	City:	EMERYVILLE
Market Cap:	245.4M	IPO Year:	2024
Target Price:	$17.83	AVG Volume (30 days):	133.4K
Analyst Decision:	Strong Buy	Number of Analysts:	7
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-2.06	EPS Growth:	N/A
52 Week Low/High:	$5.50 - $12.74	Next Earning Date:	05-14-2024
Revenue:	$47,258,000	Revenue Growth:	N/A
Revenue Growth (this year):	-33.65%	Revenue Growth (next year):	9.61%

Share on Social Networks:

Stock Insider Trading Activity of METAGENOMI INC (MGX)

Name	Ticker	Relationship	Date	Transaction	Cost Per Share	Shares	Total Value	Securities Owned After Transaction(s)	SEC Form 4
Novo Holdings A/S	MGX	10% Owner	Feb 9 '24	Buy	$10.25	100,000	$1,025,000.00	100,000	SEC Form 4
Novo Holdings A/S	MGX	10% Owner	Feb 9 '24	Buy	$15.00	800,000	$12,000,000.00	1,739,175	SEC Form 4